Paclitaxel
Sources, Chemistry, Anticancer Actions, and Current Biotechnology
- 1st Edition - October 8, 2021
- Imprint: Academic Press
- Editors: Mallappa Kumara Swamy, T. Pullaiah, Zhe-Sheng Chen
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 9 5 1 - 8
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 9 5 2 - 5
Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology provides a comprehensive survey of Paclitaxel and its derivatives chemistry, biosynthesis and antic… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePaclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology provides a comprehensive survey of Paclitaxel and its derivatives chemistry, biosynthesis and anticancer activities. In addition, biotechnological methods, including cell cultures, the use of bioreactors and metabolic engineering strategies to improve Paclitaxel production are also discussed. The book discusses topics such as mechanisms of action against cancer, novel forms of Paclitaxel for an effective cancer treatment, strategies for enhancing its bioavailability, and the application of nanocarriers for its delivery and chemotherapy of cancer.
This is a valuable resource for cancer researchers, biotechnologists and members of biomedical field who are interested in the promising anticancer qualities of this antineoplastic drug and how to enhance them for better treatments.
- Presents detailed information about Paclitaxel research, from its discovery to clinical uses and biotechnological routes of commercial production
- Focuses on Paclitaxel development as an effective chemotherapeutic drug, along with its application in different types of cancers
- Encompasses descriptive illustrations and workflows to help the reader fully understand the content and easily apply it to their research
Graduate students and researchers on cancer and biotechnology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- 1: Introduction to cancer and treatment approaches
- Abstract
- 1.1: Introduction
- 1.2: About cancer biology: Causes and risk factors
- 1.3: Cancer types, classification, and grading
- 1.4: Therapeutic interventions for cancer
- 1.5: Advanced approaches for cancer treatment
- 1.6: Conclusions
- 2: Taxol: Occurrence, chemistry, and understanding its molecular mechanisms
- Abstract
- 2.1: Introduction
- 2.2: About taxol and its discovery
- 2.3: Natural resources of taxol
- 2.4: Chemistry of taxol
- 2.5: Mechanisms of action of taxol
- 2.6: Conclusion and future prospects
- 3: Taxol: Mechanisms of action against cancer, an update with current research
- Abstract
- Acknowledgment
- 3.1: The discovery and evolution of Paclitaxel (Taxol)
- 3.2: Paclitaxel (Taxol) induces mitotic cell cycle arrest
- 3.3: Taxol induces gene-directed apoptosis
- 3.4: Taxol and calcium-dependent apoptosis
- 3.5: Immunomodulation effects by Taxol
- 3.6: Resistance mechanisms of Taxol
- 3.7: Conclusion
- 4: Application of nanocarriers for paclitaxel delivery and chemotherapy of cancer
- Abstract
- 4.1: Introduction
- 4.2: Nanoparticles
- 4.3: Liposomes
- 4.4: Dendrimers
- 4.5: Micelles
- 4.6: Nanotubes
- 4.7: Niosomes
- 4.8: Proniosomes
- 4.9: Ethosomes
- 4.10: Microparticles
- 4.11: Carbon dots
- 4.12: Clinical trials
- 4.13: Overcoming paclitaxel resistance by using Nanocarriers
- 4.14: Selected patents for paclitaxel formulations
- 4.15: Conclusion
- 5: Strategies for enhancing paclitaxel bioavailability for cancer treatment
- Abstract
- 5.1: Introduction
- 5.2: Alternative paclitaxel sources
- 5.3: Strategies of paclitaxel biosynthesis improvement in plant cell culture
- 5.4: Mathematical modeling for paclitaxel biosynthesis optimization
- 5.5: Concluding remarks and future perspectives
- 6: Botany of paclitaxel producing plants
- Abstract
- 6.1: History of taxol
- 6.2: Botany of Taxus
- 6.3: Enumeration of taxol producing plant species
- 6.4: Taxol from angiosperms
- 6.5: Conclusions and future direction
- 7: Propagation of paclitaxel biosynthesizing plants
- Abstract
- 7.1: Introduction
- 7.2: Propagation
- 7.3: Micropropagation
- 7.4: Conclusions
- 8: Endophytes for the production of anticancer drug, paclitaxel
- Abstract
- 8.1: Introduction
- 8.2: Paclitaxel sources in nature
- 8.3: Available approaches for paclitaxel production
- 8.4: Endophytes producing paclitaxel from different host plant species
- 8.5: Anticancer properties of endophytes-derived paclitaxel
- 8.6: Conclusions
- 9: Metabolic engineering strategies to enhance the production of anticancer drug, paclitaxel
- Abstract
- 9.1: Introduction
- 9.2: Historical perspective of paclitaxel
- 9.3: Metabolic engineering strategies for paclitaxel production
- 9.4: Conclusions
- 10: Paclitaxel and chemoresistance
- Abstract
- 10.1: Introduction
- 10.2: Mechanisms of chemoresistance
- 10.3: Clinical markers of paclitaxel resistance
- 10.4: Strategies to overcome paclitaxel resistance
- 10.5: Summary
- 11: Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy
- Abstract
- 11.1: Introduction
- 11.2: Microtubule stabilization and anti-mitotic mechanisms
- 11.3: Mitotic catastrophe
- 11.4: Non-mitotic mechanisms
- 11.5: Importance of micronucleation
- 11.6: Innate immunity leading to the bystander effect
- 11.7: Cellular retention of paclitaxel
- 11.8: Combination therapy
- 11.9: Prospective: New formulation of paclitaxel and additional microtubule stabilizing drugs
- 11.10: Conclusions
- 12: An update on paclitaxel treatment in breast cancer
- Abstract
- Acknowledgment
- 12.1: Introduction
- 12.2: Types of breast cancer
- 12.3: Molecular mechanism of paclitaxel in breast cancer
- 12.4: Paclitaxel treatment in different types of breast cancer
- 12.5: Adverse events and resistance due to paclitaxel treatment
- 12.6: Efficiency of other anti-cancer drugs over paclitaxel
- 12.7: Conclusions
- 13: Paclitaxel conjugated magnetic carbon nanotubes induce apoptosis in breast cancer cells and breast cancer stem cells in vitro
- Abstract
- Acknowledgments
- Conflict of interest statement
- 13.1: Introduction
- 13.2: Experimental details
- 13.3: Results and discussion
- 13.4: Conclusions
- Index
- Edition: 1
- Published: October 8, 2021
- No. of pages (Paperback): 354
- No. of pages (eBook): 354
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323909518
- eBook ISBN: 9780323909525
MS
Mallappa Kumara Swamy
Mallappa Kumara Swamy, PhD, completed his Postdoctoral Research at the Department of Crop Science, Faculty of Agriculture, Universiti Putra Malaysia (UPM), from 2014-2018. He has more than 16 years of teaching and research experience in the fields of plant biotechnology, secondary metabolites production, phytochemistry and bioactive studies. Dr. Swamy has published more than 100 research publications in peer- reviewed journals, 25 book chapters and has edited 10 books with reputed international publishers. His research focuses on the area of natural products, plant cell, tissue culture technology for bioactive compounds production and evaluation of their bioactivities, and nanobiotechnology for medical applications.
Affiliations and expertise
Professor, Department of Biotechnology at East West First Grade College (Affiliated to Bangalore University), IndiaTP
T. Pullaiah
Professor T. Pullaiah is a former Professor at the Department of Botany at Sri Krishnadevaraya University in Andhra Pradesh, India, where he has taught for more than 35 years. He was President of Indian Botanical Society (2014), President of the Indian Association for Angiosperm Taxonomy (2013). He was awarded the Panchanan Maheshwari Gold Medal, the Prof. P.C.Trivedi Medal, the Dr. G. Panigrahi Memorial Lecture award of the Indian Botanical Society and Prof. Y.D. Tyagi Gold Medal of the Indian Association for Angiosperm Taxonomy. Under his guidance 54 students obtained their doctoral degrees. He has authored 52 books, edited 23 books and published over 330 research papers, including reviews and book chapters. He was also a member of Species Survival Commission of the International Union for Conservation of Nature (IUCN). Professor Pullaiah received his PhD from Andhra University, India, attended Moscow State University, Russia, and worked as Post-Doctoral Fellow
Affiliations and expertise
Department of Botany, Sri Krishnadevaraya University, Anantapur, IndiaZC
Zhe-Sheng Chen
Zhe-Sheng Chen, PhD, opened the St. John’s University’s first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen has over 170 papers published, co-edited Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy book (Elsevier), and holds 5 patents.
Affiliations and expertise
Editor of "African Journal of Pharmacy and Pharmacology"; Editor-in-Chief “Journal of Cancer Research Updates" and "Journal of New Developments in Chemistry"Read Paclitaxel on ScienceDirect